N-[(2S)-2-isocyanato-3,3-dimethylbutyl]-N-methylthiophene-2-sulfonamide | 848776-91-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: N-[(2S)-2-isocyanato-3,3-dimethylbutyl]-N-methylthiophene-2-sulfonamide
• CAS: 848776-91-0
• 化学式: C₁₂H₁₈N₂O₃S₂
• 分子量: 302.419
• InChiKey: XJIJRZSOIGKMPE-SNVBAGLBSA-N

物化性质

• 沸点：
  409.9±51.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  103
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  N-[(2S)-2-isocyanato-3,3-dimethylbutyl]-N-methylthiophene-2-sulfonamide 、 N-allyl-2-((3S,13S,16aS,17aR,17bS)-13-amino-17,17-dimethyl-1,14-dioxohexadecahydro-2H,12H-cyclopropa[3,4]pyrrolo[1,2-e][1]oxa[5,8]diazacyclohexadecin-3-yl)-2-oxoacetamide hydrochloride 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 (16aS,17aR,7bS)-13(S)-[[[[2,2-dimethyl-1(S)-[[methyl(2-thienylsulfonyl)amino]methyl]propyl]amino]carbonyl]amino]-hexadecahydro-17,17-dimethyl-α,1,14-trioxo-N-(2-propenyl)-2H,12H-cyclopropa[3,4]pyrrolo[1,2-e][1,5,8]oxadiazacyclohexadecine-3(S)-acetamide
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Oxygen-Containing Macrocyclic Peptidomimetics as Inhibitors of HCV NS3 Protease

  摘要：

  HCV infection is considered a silent epidemic because most people infected do not develop acute symptoms. Instead, the disease progresses to a chronic state leading to cirrhosis and hepatocarcinoma. Novel therapies are needed to combat this major health threat. The HCV NS3 serine protease has been the target of continuous investigation because of its pivotal role in viral replication. Herein, we present the P1-P3 macrocyclization approach followed for identification of HCV NS3 inhibitors as potential back-up candidates to our first generation drug candidate, Sch 503034 (1). Different P1-P3 linkers were investigated to identify novel macrocyclic scaffolds. SAR exploration of P3-caps in the macrocyclic cores allowed the identification of L-serine derived macrocycle 32 (K-i* = 3 nM, EC90 = 30 nM) and allo-threonine derived macrocycle 36 (K-i* = 3 nM, EC90 = 30 nM) as potent HCV NS3 protease inhibitors.

  DOI：

  10.1021/jm801201u
• 作为产物：
  描述：

  光气 、 N-[(2S)-2-amino-3,3-dimethylbutyl]-N-methylthiophene-2-sulfonamide 在 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 2.0h， 生成 N-[(2S)-2-isocyanato-3,3-dimethylbutyl]-N-methylthiophene-2-sulfonamide
  参考文献：
  名称：

  Acylsulfonamide compounds as inhibitors of hepatitis C virus NS3 serine protease

  摘要：

  本发明公开了具有HCV蛋白酶抑制活性的新化合物，以及制备这种化合物的方法。在另一实施例中，本发明公开了包含这种化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。

  公开号：

  US20060046956A1

文献信息

• 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis C virus NS3 serine protease
  申请人：Njoroge George F.

  公开号：US20050197301A1

  公开（公告）日：2005-09-08

  The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.

  本发明公开了具有HCV蛋白酶抑制活性的新化合物，以及制备这种化合物的方法。在另一实施方式中，本发明公开了包含这种化合物的药物组合物，以及使用它们治疗与HCV蛋白酶相关的疾病的方法。
• Methods for treating hepatitis C
  申请人：Albrecht K. Janice

  公开号：US20060276405A1

  公开（公告）日：2006-12-07

  Methods of treating hepatitis C are provided comprising using a therapeutically effective amount of at least one novel hepatitis C (“HCV”) protease inhibitor or, alternatively, at least one antiviral or immuno-modulating HCV agent, which is not an HCV protease inhibitor, for a first treatment period. Subsequently, a combination of the at least one novel hepatitis C (“HCV”) protease inhibitor and the at least one antiviral or immuno-modulating HCV agent are administered in a therapeutically effective amount for a second treatment period. The methods are provided for treating a wide variety of diseases, disorders and symptoms associated with hepatitis C virus by modulating the activity of HCV protease (for example HCV NS3/NS4a serine protease) in a subject.

  提供了治疗丙型肝炎的方法，包括使用至少一种新型丙型肝炎（“HCV”）蛋白酶抑制剂的治疗有效量，或者选择至少一种不是HCV蛋白酶抑制剂的抗病毒或免疫调节HCV药物，用于第一治疗期。随后，在第二治疗期内以治疗有效量给予至少一种新型丙型肝炎（“HCV”）蛋白酶抑制剂和至少一种抗病毒或免疫调节HCV药物的组合。这些方法用于通过调节受试者中HCV蛋白酶（例如HCV NS3/NS4a丝氨酸蛋白酶）的活性来治疗与丙型肝炎病毒相关的各种疾病、疾病和症状。
• Controlled-release formulation
  申请人：Malcolm A. Bruce

  公开号：US20060275366A1

  公开（公告）日：2006-12-07

  Controlled-release dosage formulations including at least one compound of Formulae I to XXVI herein and a controlled-release carrier and methods of treatment using the same are provided.

  提供了包括本文中的至少一种I到XXVI式化合物和控释载体的控释剂量制剂，以及使用它们的治疗方法。
• Pharmaceutical formulations and methods of treatment using the same
  申请人：Malcolm A. Bruce

  公开号：US20070010431A1

  公开（公告）日：2007-01-11

  Pharmaceutical formulations containing at least one compound of Formulae I-XXVI herein and at least one surfactant. Pharmaceutically acceptable carriers and excipients may also be included in the formulations. The formulations of the present invention are suited for use in single unit dosages.

  含有本文中的至少一种I-XXVI式化合物和至少一种表面活性剂的制药配方。 制剂中还可以包括药用可接受的载体和辅料。 本发明的制剂适用于单剂量使用。
• WO2006/130553
  申请人：——

  公开号：——

  公开（公告）日：——